{
    "nct_id": "NCT05799248",
    "official_title": "Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management",
    "inclusion_criteria": "1. Patient willing to provide signed informed consent and willing to comply with all required study schedule events, where safe and feasible.\n2. Patient is male and aged >18 years old.\n3. Histologically confirmed adenocarcinoma of the prostate.\n4. High risk prostate cancer. High-risk patients will be defined as having any of the following criteria: primary Gleason grade 4, or any Gleason grade 5, PSA â‰¥20, or clinical stage T3a (per NCCN Guidelines Version 2.2019; PROS-2).\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Patients with any medical condition or circumstance (including receiving an IP) that the investigator believes may compromise the data collected or lead to a failure to fulfil the study requirements.\n2. Patients who are planned to have an x-ray contrast agent or other PET radiotracer <24 hours prior to the PET scan.\n3. Patients currently receiving, or with a prior history of, androgen deprivation therapy (ADT; defined as surgical orchidectomy; luteinizing hormone-releasing hormone [LHRH] agonist alone [continuous or intermittent]; LHRH antagonist alone [continuous or intermittent]; administration or use of a first generation or second generation anti-androgen alone or in combination with an LHRH agonist/antagonist).\n4. Patients participating in an interventional clinical trial within 30 days and having received an IP within five biological half-lives prior to administration of rhPSMA-7.3.",
    "miscellaneous_criteria": ""
}